Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) Short Interest Up 9.6% in December

Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) was the target of a significant increase in short interest during the month of December. As of December 29th, there was short interest totalling 9,749,519 shares, an increase of 9.6% from the December 15th total of 8,894,839 shares. Approximately 14.2% of the company’s shares are sold short. Based on an average daily volume of 2,362,490 shares, the short-interest ratio is presently 4.1 days.

Shares of Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) opened at $2.90 on Monday. Ampio Pharmaceuticals has a one year low of $0.38 and a one year high of $4.95. The stock has a market capitalization of $191.51, a PE ratio of -14.50 and a beta of 0.51.

A hedge fund recently bought a new stake in Ampio Pharmaceuticals stock. Creative Planning acquired a new stake in shares of Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 28,500 shares of the specialty pharmaceutical company’s stock, valued at approximately $116,000.

Separately, ValuEngine raised Ampio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 11th.

COPYRIGHT VIOLATION WARNING: This news story was originally published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.truebluetribune.com/2018/01/22/ampio-pharmaceuticals-inc-ampe-sees-significant-growth-in-short-interest-2.html.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply